Hunting Hill Global Capital’s Alexion Pharmaceuticals ALXN Stock Holding History

Hunting Hill Global Capital’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-174,236	Closed	-$32M	–	118
2021 Q2	$32M	Buy	174,236 +3,535	+2%	+$607K	9.23%	4
2021 Q1	$26.1M	Buy	+170,701	New	+$26.4M	8.4%	2

Other funds holding ALXN

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Hunting Hill Global Capital's ALXN Position: Q3 2021 in Review

Hunting Hill Global Capital sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 174,236 shares — an estimated $32M sold.

Hunting Hill Global Capital first reported a position in ALXN in Q1 2021 and held it in 2 quarters. The position peaked at $32M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Hunting Hill Global Capital reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Hunting Hill Global Capital sold 174,236 Alexion Pharmaceuticals shares in Q3 2021, an estimated $32M.
Hunting Hill Global Capital first reported a position in Alexion Pharmaceuticals in Q1 2021 and held it in 2 quarters.
Hunting Hill Global Capital's Alexion Pharmaceuticals position peaked at $32M in Q2 2021.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Hunting Hill Global Capital's 13F filing for Q3 2021, filed 15 Nov 2021.